Brokers Issue Forecasts for TSE:MSL Q1 Earnings

Merus Labs International Inc. (TSE:MSL) (NASDAQ:MSLI) – Equities researchers at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Merus Labs International in a report released on Monday, March 30th. HC Wainwright analyst A. He forecasts that the specialty pharmaceutical company will post earnings of ($0.56) per share for the quarter. HC Wainwright also issued estimates for Merus Labs International’s Q2 2027 earnings at ($0.60) EPS, Q3 2027 earnings at ($0.64) EPS and Q4 2027 earnings at ($0.70) EPS.

Separately, Cantor Fitzgerald raised Merus Labs International to a “strong-buy” rating in a report on Wednesday, March 11th. One research analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, Merus Labs International has an average rating of “Strong Buy”.

Merus Labs International Price Performance

Merus Labs International has a one year low of C$0.95 and a one year high of C$1.76.

About Merus Labs International

Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates.